DIRS.INFO The most relevant business & tech news

☆ Analysts love these biotech stocks, giving 4 more than 100% upside
▼ + stars: | 2024-01-25 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.

Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals

☆ 3M names Bryan Hanson as CEO of its health care business
▼ + stars: | 2023-08-22 | by ( ) www.reuters.com time to read: +1 min

REUTERS/Nicholas Pfosi/File Photo Acquire Licensing RightsAug 22 (Reuters) - 3M Co (MMM.N) said on Tuesday that Bryan Hanson would be the chief executive officer of the healthcare company it plans to spin off. 3M last year disclosed plans to spin off its healthcare business into a listed company, in which the U.S. industrial giant would retain a 19.9% stake. The health care unit, which focuses on wound care, oral care and healthcare technology, accounted for about 25% of 3M's $34.23 billion in sales last year. Hanson joins 3M from Indiana-based medical equipment maker Zimmer Biomet (ZBH.N), where he was president and CEO since 2017, and chairman since 2021. Hanson would join 3M on Sept. 1 as CEO of Health Care Business Group, the company said.

Persons: Nicholas Pfosi, Bryan Hanson, Hanson, Zimmer Biomet, Carrie Cox, Kannaki, Shilpi Majumdar Organizations: REUTERS, Health Care Business Group, Humacyte Inc, 3M, Thomson Locations: Maplewood , Minnesota, U.S, Indiana, Bengaluru

☆ Alleged Russian crime boss sanctioned by Ukraine owns a major stake in US biotech firm
▼ + stars: | 2023-08-21 | by ( Matt Egan | ) edition.cnn.com time to read: +13 min

Buried in corporate filings is another relationship that is central to Humacyte: Russian billionaire Gavril Yushvaev is the company’s second-largest individual shareholder. Humacyte: Russian billionaire has no ‘control’ over firmYushvaev has not been sanctioned by the US government. “There are patients walking today on their own limbs who would not be doing so without access to the HAV to repair their damaged arteries,” a Humacyte spokesperson said. ‘It shows poor judgment’Yushvaev was brought in as an accredited private investor by Credit Suisse’s capital markets advisory group, a Humacyte spokesperson told CNN. Dougan does not personally know Yushvaev, a Humacyte spokesperson told CNN.

Persons: — Weeks, Kathleen Sebelius, Gavril Yushvaev, Yushvaev –, ”, Yushvaev, ” Forbes, Dann, Charles Whitehead, That’s, Steven Tian, Putin, Vladimir Putin, Trump, Sebelius, Humacyte, Obama, ” Yushvaev, Yale’s Tian, Whitehead, “, ” It’s, Brady Dougan, Dougan, Laura Niklason, ’ Yushvaev, Jeff Sonnenfeld, Sonnenfeld, ” Humacyte, Lawrence Ward, Ward, Eleanor Bloxham, ” Bloxham, ’, Lyft, Mother Jones Organizations: New York CNN, Pentagon, Nasdaq, US Department of Defense, CNN, Securities and Exchange Commission, Ukraine, Pepsico, Cornell Law School, BlackRock, Vanguard, Yale School of Management’s, Institute, Treasury Department, Kremlin, Credit, Ayabudge, Credit Suisse, Humacyte, PTC, Yale, Yushvaev, SEC, “, Soviet, US Treasury, Dorsey, Whitney’s, Value Alliance, The Department of Defense, DOD, Cornell, Russia Locations: Ukraine, North Carolina, Humacyte, Russian, Russia, Crimea, Cypriot, Yale, Bloxham, Lyft

☆ How surgeons in Ukraine are saving soldiers' lives with a simple tube grown from human cells
▼ + stars: | 2023-06-25 | by ( Adam Barnes | ) www.businessinsider.com time to read: +6 min

It's a small tube called the human acellular vessel (HAV) designed to treat traumatic vascular injuries mostly due to blasts and shrapnel. Why vascular injuries are so dangerousVascular injuries are a leading cause of preventable death in military combat and a leading cause of amputation. They're lab-grown from human vascular cells in about eight weeks and then sanitized to be ready as an off-the-shelf replacement blood vessel. HumacyteVascular surgeons often treat traumatic vascular injuries with grafts. Humacyte plans to file an application with the FDA later this year for HAVs to treat traumatic vascular injuries.

Persons: HAVs, —, Oleksandr Sokolov, Sokolov, Humacyte, Laura Niklason, they're, Niklason, Niklosan, Jeffrey Lawson Sokolov, HAVs aren't, Miechia, Esco, What's Organizations: Service, FDA's, International, Ukrainian Ministry of Health, Humacyte, Humactye, FDA, HAVs Locations: Ukraine, It's, Afghanistan, Russia

Search resuls for: "Humacyte"

4 mentions found